Possible Bearish Signals With Relay Therapeutics Insiders Disposing Stock
This article examines recent insider selling at Relay Therapeutics (NASDAQ:RLAY), where executives and directors have disposed of a significant amount of stock over the last year. Despite a strong financial performance shown in the latest quarterly report, the consistent selling could be interpreted as a bearish signal, suggesting that insiders might believe the stock is overvalued or that future growth may not meet expectations. The analysis highlights the importance of observing insider transaction patterns as an indicator of potential future stock performance.
JonesTrading Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $20
JonesTrading has reiterated its Buy rating for Relay Therapeutics (RLAY.US) and maintained its price target at $20. This indicates the firm's continued confidence in the company's stock performance.
Relay Therapeutics Stock In Focus As Phase 3 Trial Begins
Relay Therapeutics has initiated a Phase 3 clinical trial for zovegalisib (RLY-2608), a PI3Ka inhibitor developed in collaboration with X-Chem. This progression into a late-stage trial highlights Relay Therapeutics' strategy of leveraging external discovery platforms to advance its oncology pipeline and share development risks. The company's investment narrative now focuses on how this drug's advancement will impact its financial outlook, with analysts forecasting significant revenue growth despite current unprofitability.
X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics
X-Chem announced a significant milestone in its collaboration with Relay Therapeutics, as Relay initiated a Phase 3 clinical trial for zovegalisib (RLY-2608). This drug candidate originated from a compound identified through X-Chem's DNA-encoded chemical library (DEL) screen, targeting PI3Ka for breast cancer treatment. Both companies highlighted the success of their collaboration and the differentiated pharmacology of the discovered compound.
Brenton Mar: Reflecting on Transformative Journey in Cancer Drug Development at Relay Therapeutics
Brenton Mar, former Senior Vice President of Clinical Development at Relay Therapeutics, reflected on his 3.5 transformative years at the company. During his tenure, Relay Therapeutics developed two FDA Breakthrough Designated drugs: lirafugratinib for cholangiocarcinoma and zovegalisib for breast cancer, and achieved proof of concept for zovegalisib in vascular malformations, along with advancing RLY-8161 for NRAS-mutant solid tumors. Mar expressed gratitude to his colleagues and shared his excitement for his next venture in the biotech world.
Relay Therapeutics stock consolidates after recent gains as investors watch pipeline progress
Relay Therapeutics stock recently consolidated below its 52-week high after a rally, closing at USD 18.84 on September 18, 2026. The clinical-stage biotechnology company's valuation is anchored by its cash reserves, which fund R&D and support its pipeline for several years, despite operating expenses exceeding revenue. Investors are closely monitoring upcoming pipeline updates and clinical trial outcomes, as these will likely determine the stock's future trajectory given the company's reliance on a limited number of late-stage assets.
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Unpacking a Potential 41% Upside in the Biotech Sector
Relay Therapeutics (RLAY) is analyzed as a high-potential biotech stock focusing on precision medicine for oncology and genetic diseases. Despite current unprofitability and negative free cash flow, the company is backed by strong analyst ratings predicting a 41% upside due to its innovative product pipeline, including RLY-2608 and RLY-8161. While technical indicators suggest it may be overbought, its long-term growth prospects make it an attractive, albeit high-risk, investment in the biotech sector.
Relay Therapeutics (NASDAQ: RLAY) CEO sells shares under preset trading plan
Relay Therapeutics' President and CEO, Sanjiv Patel, sold 48,199 shares of common stock on September 8, 2026, at an average price of $18.94 per share, as part of a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Patel directly holds 519,500 shares and indirectly holds additional shares through family trusts. The sale was executed within a price range of $18.33 to $19.25, and he disclaims beneficial ownership of the shares held in the trusts.
Relay Therapeutics Insider Sold Shares Worth $912,889, According to a Recent SEC Filing
Sanjiv Patel, a Director, President, and CEO at Relay Therapeutics (RLAY), sold 48,199 shares of the company's stock on September 8, 2026. This transaction amounted to $912,889. The article provides details of this insider trading activity based on a recent SEC filing.
Relay Therapeutics (RLAY) R&D chief sells stock under 10b5-1 plan
Donald A. Bergstrom, President, R&D at Relay Therapeutics (RLAY), sold 8,530 shares of common stock on September 8, 2026, at a weighted average price of $18.97 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in October 2025. Following the sale, Bergstrom directly holds 399,130 shares, including those underlying restricted stock units.
Relay Therapeutics R&D president sells $161,814 in stock
Donald A. Bergstrom, President of Research & Development at Relay Therapeutics (NASDAQ:RLAY), sold 8,530 shares of company stock for approximately $161,814 on September 8, 2026. This transaction occurred under a Rule 10b5-1 trading plan, following a significant 370% surge in the stock over the past year. Despite the sale and the stock appearing overvalued by InvestingPro's Fair Value analysis, several analysts have recently reiterated "Buy" ratings and raised price targets for Relay Therapeutics, citing progress in its cancer treatment pipeline.
Relay Therapeutics Insider Sold Shares Worth $912,889, According to a Recent SEC Filing
An insider at Relay Therapeutics (RLAY) sold shares valued at $912,889, as reported in a recent SEC filing. This transaction follows other recent insider sales and news regarding the company's presentation at a healthcare conference. Relay Therapeutics' stock performance shows a significant year-to-date increase.
Relay Therapeutics (NASDAQ: RLAY) officer eyes another stock sale after June trade
An officer at Relay Therapeutics (RLAY), Peter Rahmer, has filed a Rule 144 notice to sell up to 50,000 shares of common stock, valued at approximately $1.028 million, through Morgan Stanley Smith Barney LLC. The planned sale is set for around August 26, 2026, on NASDAQ, stemming from Restricted Stock Units granted in January 2025. This follows a previous sale by Rahmer of 50,000 shares for $954,560 on June 30, 2026, under a 10b5-1 plan.
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Relay Therapeutics, Inc. announced its management will participate in two investor fireside chats in September 2026. These events include the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference. The company, a clinical-stage precision medicine firm, will webcast these events live on its investor relations website.
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Relay Therapeutics, a clinical-stage precision medicine company, announced its participation in two investor conferences in September: the Wells Fargo Healthcare Conference on September 8, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. Management will hold fireside chats at both events, which will be webcast live on the company's website. The company is focused on developing therapies for cancer and genetic diseases using its Dynamo® platform.
Relay Therapeutics management will join two live online talks this month
Relay Therapeutics (Nasdaq: RLAY) announced that its management will participate in two upcoming investor fireside chats in September 2026. These include the Wells Fargo Healthcare Conference on September 8, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. Live webcasts and 30-day replays will be available on the company's investor relations website for both events.
Relay Therapeutics director SVF Pauling (Cayman) sells $116.4m
SVF Pauling (Cayman) Ltd, a director and 10% owner of Relay Therapeutics (NASDAQ: RLAY), sold 6 million shares of common stock for approximately $116.4 million on August 25, 2026. This divestment follows a significant 426% surge in the stock price over the past year, with the company's market capitalization reaching $4.26 billion. InvestingPro analysis suggests the stock is currently overvalued, potentially influencing the timing of the sale.
Relay Therapeutics (NASDAQ: RLAY) holder plans sale of up to 6M shares
SVF Pauling (Cayman) Ltd, a stockholder of Relay Therapeutics (NASDAQ: RLAY), plans to sell up to 6 million shares of common stock with an aggregate market value of $123.42 million through Citigroup Global Markets Inc. on NASDAQ. These shares were acquired in December 2018 through the automatic conversion of Series C Convertible Preferred Stock during Relay Therapeutics’ IPO. The proposed sale date is August 25, 2026, and this Rule 144 filing indicates a neutral impact and sentiment.
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $29
H.C. Wainwright has reiterated its Buy rating for Relay Therapeutics (RLAY.US) and maintained its price target of $29. This indicates continued confidence from the analyst firm in the company's prospects.
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $29
H.C. Wainwright has reiterated its Buy rating on Relay Therapeutics (RLAY.US) and increased the target price for the company's stock to $29. This adjustment reflects the firm's continued confidence in Relay Therapeutics' prospects.
H.C. Wainwright raises Relay Therapeutics price target to $29
H.C. Wainwright increased its price target for Relay Therapeutics (NASDAQ: RLAY) to $29 from $28, maintaining a Buy rating, following the company's Q2 net loss report. Despite the loss and higher-than-estimated expenses, Relay Therapeutics holds a strong cash position of $910.9 million, providing an operational runway into 2029. The stock has seen a significant 510% return over the past year, although InvestingPro analysis suggests it may be overvalued based on fair value.
RLAY Maintained by HC Wainwright & Co. -- Price Target Raised to $29
HC Wainwright & Co. has maintained a "Buy" rating for Relay Therapeutics (RLAY) and raised its price target to $29, reflecting cautious optimism despite the company's financial challenges. However, GuruFocus's GF Value™ indicates RLAY is significantly overvalued by 493.4%, and its GF Score™ of 42/100 points to major weaknesses in profitability and valuation. Insider selling activity also suggests a lack of confidence from company insiders.
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says
HC Wainwright has increased its price target for Relay Therapeutics (NASDAQ:RLAY) to $29 from $28, maintaining a "buy" rating and projecting a 39.8% upside. Despite a recent quarterly loss of $0.41 per share and revenue below estimates, analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and an average target price of $25.92. Insider selling by CEO Sanjiv Patel and Peter Rahmer was also noted, alongside significant institutional investment in the company.
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE
Bank of America Corp DE significantly increased its stake in Relay Therapeutics (NASDAQ:RLAY) by 86.1% during the first quarter, now owning 1.01% of the company's stock valued at $19.28 million. Other institutional investors and hedge funds also made substantial changes to their positions, with 96.98% of the company's stock owned by institutional investors. Insiders have sold a considerable amount of shares recently, while analysts maintain a "Moderate Buy" rating with a consensus target price of $25.83.
Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified?
Relay Therapeutics (RLAY) reported Q2 2026 results with revenue of US$0.35 million and a net loss of US$83.71 million. Despite recent share price recovery, the company's P/B ratio of 5.1x is higher than its peers and the broader biotech industry, suggesting it is overvalued. Investors are advised to consider the ongoing net losses and reliance on clinical trial progress as key risks.
Relay Therapeutics (RLAY) Stock May Be Fully Valued After A 7x Run
Relay Therapeutics (RLAY) stock has seen a significant 7x return over the past year but appears overvalued based on broad valuation checks. The company passes only one of six valuation metrics and trades at a P/B ratio of 5.1x, higher than the biotech industry average of 2.5x. While future drug development potential could justify the price, the current valuation relies heavily on the company's pipeline and execution given its current loss-making status.
Timothy G. Youngquist 2020 Irrevocable Trust Boosts Stake in Relay Therapeutics, Inc. $RLAY
The Timothy G. Youngquist 2020 Irrevocable Trust significantly increased its stake in Relay Therapeutics, Inc. (RLAY) by 60.6% in the second quarter, now owning 801,464 shares valued at approximately $15 million. This move comes despite recent insider selling by executives and the company missing quarterly EPS and revenue estimates. Analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $25.83.
Handelsbanken Fonder AB Buys New Shares in Relay Therapeutics, Inc. $RLAY
Handelsbanken Fonder AB recently purchased 59,100 shares of Relay Therapeutics (NASDAQ:RLAY) valued at $1.1 million, while other institutional investors also adjusted their holdings. Insiders at Relay Therapeutics have sold a significant number of shares, totaling $7.23 million over the last 90 days. Despite the insider selling and missed quarterly earnings expectations, analysts maintain a "Moderate Buy" consensus rating for the company with an average price target of $25.83.
Relay Therapeutics Insider Sold Shares Worth $979,886, According to a Recent SEC Filing
An insider at Relay Therapeutics (RLAY) sold shares valued at $979,886, as reported in a recent SEC filing. This transaction occurred on August 18, 2026, and is one of several insider share sales reported around the same date. Relay Therapeutics is a clinical-stage biotechnology company focused on developing therapies for cancer and genetic diseases.
Relay Therapeutics (RLAY) CFO sells shares via preset trading plan
Relay Therapeutics (RLAY) Chief Financial Officer, Thomas Catinazzo, sold 17,717 shares of common stock on August 14, 2026, at a weighted average price of $19.74 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on October 30, 2025. Following the sale, Catinazzo directly holds 140,568 shares of Relay Therapeutics common stock, which includes restricted stock units.
Relay Therapeutics (RLAY) CEO sells 48K shares in plan trade
Relay Therapeutics (RLAY) President and CEO Sanjiv Patel sold 48,199 shares of common stock on August 17, 2026, at a weighted average price of $20.33 per share. This transaction was conducted under a Rule 10b5-1 trading plan adopted in October 2025. Following the sale, Patel directly holds 567,699 shares, with additional shares held indirectly in family trusts for which he disclaims beneficial ownership.
Relay Therapeutics stock hits 52-week high at 20.83 USD
Relay Therapeutics stock reached a 52-week high of $20.83, currently trading at $20.87 with a market capitalization of $4.52 billion and a 1-year return of 496%. Despite trading above its Fair Value according to InvestingPro, the surge reflects investor confidence. Several analysts have raised price targets and reiterated Buy ratings, citing progress in breast cancer treatment development, particularly for its lead asset zovegalisib.
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
The Zacks Analyst Blog highlights four AI-powered drug discovery stocks: Recursion Pharmaceuticals (RXRX), Schrödinger (SDGR), Relay Therapeutics (RLAY), and Absci (ABSI). These companies leverage AI and computational platforms to accelerate drug discovery, reduce costs, and improve success rates in pharmaceutical research. Each company has unique approaches, proprietary technologies, and advancing clinical pipelines, offering investors exposure to the transformative potential of AI in drug development.
Persistent Asset Partners Ltd Makes New $1.32 Million Investment in Relay Therapeutics, Inc. $RLAY
Persistent Asset Partners Ltd invested $1.32 million in Relay Therapeutics, acquiring 70,693 shares during Q2. This comes as Relay Therapeutics reported a quarterly loss and revenue miss, while company insiders sold approximately $7.23 million in stock over the past 90 days. Despite mixed analyst sentiment, the stock holds a consensus "Moderate Buy" rating with an average target price of $25.83.
Relay Therapeutics (NASDAQ:RLAY) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen has downgraded Relay Therapeutics (NASDAQ:RLAY) from a "Hold" to a "Sell" rating, despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $25.83. This downgrade follows the company's recent quarterly earnings report, where it missed both EPS and revenue estimates. Additionally, insider selling amounting to $7.23 million over the past 90 days was noted, while institutional investors hold a significant 96.98% stake.
PERCEPTIVE ADVISORS LLC Expands Relay Therapeutics Inc (RLAY) Stake -- Shares Look 421% Overvalued on GF Value
Perceptive Advisors LLC significantly increased its stake in Relay Therapeutics Inc (RLAY) by purchasing 13.67 million shares, bringing their total ownership to 6.40%. Despite this strong conviction from a specialized healthcare investment firm, GuruFocus identifies RLAY shares as "Significantly Overvalued" by 421% based on its GF Value, raising concerns for value investors even with the company's strong balance sheet and growth potential. The article highlights the discrepancy between market sentiment and intrinsic value, urging caution despite favorable short-term technical indicators.
Relay Therapeutics (RLAY): Commodore Capital group discloses 12M-share, 5.5% position
Commodore Capital LP and its affiliates, including Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, have disclosed a beneficial ownership of 12,000,000 shares of Relay Therapeutics, Inc. (RLAY) common stock. This stake represents 5.5% of the outstanding common stock, based on 218,531,200 shares as of June 30, 2026. The group reports shared voting and shared dispositive power over these shares, with Commodore Capital LP acting as investment manager and Atkinson and Kramarz exercising investment discretion.
Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year
Relay Therapeutics (RLAY), a clinical-stage precision medicines company in targeted oncology with a $4.4 billion market cap, has seen its stock surge by 486% over the past year, trading near a new 3-year high. While technical momentum is strong with a 100% "Buy" opinion from Barchart and a Trend Seeker "Buy" signal, the company's fundamentals indicate an expected revenue decrease of over 30% this year, though it is projected to rise by 60.64% next year. Analysts are largely positive on the stock's future, despite its highly speculative nature, with price targets ranging from $20 to $32.
Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year
Relay Therapeutics (RLAY), a clinical-stage precision medicines company, has seen its stock surge by nearly 500% over the past year, trading near a new 3-year high. While technical momentum is strong, with a "Buy" signal from Barchart's Trend Seeker, the company's fundamentals indicate a projected revenue decrease of over 30% this year, though it is expected to rise significantly next year. Analysts are largely bullish on the stock, despite its speculative nature, due to its focus on collaboration and licensing revenue in targeted oncology.
Relay Therapeutics, Inc. $RLAY Shares Bought by California State Teachers Retirement System
California State Teachers Retirement System increased its stake in Relay Therapeutics (NASDAQ:RLAY) by 47.9% in the first quarter, now owning 174,099 shares valued at $1.73 million. Despite institutional ownership of nearly 97%, the company missed analyst expectations on its last quarterly earnings and revenue. Insiders have also sold a significant amount of shares recently, totaling $7.23 million over 90 days.
These Analysts Think Relay Therapeutics, Inc.'s (NASDAQ:RLAY) Sales Are Under Threat
Analysts have downgraded their revenue forecasts for Relay Therapeutics, Inc. (NASDAQ:RLAY) for 2026, cutting estimates from US$12m to US$11m and increasing expected losses per share to US$1.60. Despite the lowered revenue projections and increased anticipated losses, the consensus price target remains largely unchanged at US$26.77. The company's revenue growth is expected to improve compared to its past performance but still trails the industry average.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Relay Therapeutics (NASDAQ:RLAY) recently released its second-quarter results, showing revenue significantly below analyst expectations and larger-than-modelled losses. As a result, analysts have cut 2026 revenue estimates and increased loss per share forecasts. Despite the weaker earnings outlook, the average price target remained unchanged, suggesting analysts do not anticipate a long-term impact on valuation, though the company's revenue decline is expected to be worse than industry peers.
These Analysts Think Relay Therapeutics, Inc.'s (NASDAQ:RLAY) Sales Are Under Threat
Analysts have downgraded their revenue forecasts for Relay Therapeutics (RLAY) for 2026, cutting estimates from US$12m to US$11m and expecting increased losses per share to US$1.60. Despite the lowered outlook, the consensus price target remains unchanged at US$26.77, suggesting that the weaker earnings are not anticipated to impact long-term valuation. The company is projected to grow faster in the future than in the past, though still slower than the broader industry.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Relay Therapeutics, Inc. (NASDAQ:RLAY) recently released its second-quarter results, showing revenue of US$350k, 56% less than analysts expected, and losses of US$0.41 per share, which were larger than modeled. Following these results, analysts have cut their 2026 revenue estimates to US$10.2m and increased their loss per share forecasts to US$1.59. Despite the downgraded outlook, the average price target remained largely unchanged at US$26.77, suggesting analysts don't foresee a long-term impact on valuation, though the company is expected to underperform the industry in revenue growth.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Following its Q2 earnings release, Relay Therapeutics, Inc. (NASDAQ:RLAY) experienced significant cuts to analyst revenue estimates for 2026 and increased loss-per-share forecasts. Despite this, the average price target remained stable at US$26.77, suggesting that the weaker short-term outlook might not impact the long-term valuation. The company's shrinking revenues are expected to moderate by 2026, though still underperforming the broader industry.
Relay Therapeutics (RLAY): Perceptive Advisors discloses 6.4% ownership stake
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have disclosed a beneficial ownership of 6.4% in Relay Therapeutics, Inc. This stake, totaling 14,106,187 shares, is held directly by the Master Fund. All reporting persons share voting and dispositive power over these shares, based on Relay Therapeutics having 219,141,631 shares outstanding as of July 31, 2026.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Just Reported And Analysts Have Been Cutting Their Estimates
The user provided an incomplete article content ("Document") and thus a meaningful summary cannot be generated. Similarly, the cleaned content cannot be provided as the full article text is missing.
Citizens raises Relay Therapeutics stock price target on progress
Citizens has increased its price target for Relay Therapeutics (NASDAQ:RLAY) shares to $26.00 from $21.00, maintaining a Market Outperform rating, based on significant progress in breast cancer treatment development. The company's stock has shown strong performance, surging 514% over the past year, and its drug zovega is viewed as having potential as a backbone treatment in breast cancer and showing promising results in vascular malformations. Despite strong momentum, InvestingPro analysis suggests the shares may be overvalued, though the company boasts a strong balance sheet.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Brokerages
Relay Therapeutics, Inc. (NASDAQ:RLAY) has received a "Moderate Buy" consensus rating from 14 analysts, with an average 12-month price target of $25.17, exceeding its current share price of $19.77. Despite recent positive analyst actions like price target increases, the company missed its latest quarterly earnings and revenue estimates. Additionally, company insiders have sold a significant number of shares totaling approximately $7.46 million over the past 90 days.
2 Things Relay Therapeutics (RLAY) Results Say About Its 4.9x P B Valuation
Relay Therapeutics reported a wider net loss and lower revenue in Q2 2026, leading to a slight pullback in its shares recently, though the stock has seen significant year-to-date gains. The company's P/B ratio of 4.9x is below its peers but still considered expensive compared to the broader US biotechs industry, reflecting market optimism for its future growth despite ongoing losses and funding risks. Investors are advised to consider the potential rewards and risks, including clinical and regulatory uncertainty, before making investment decisions.
